Switch theme
Sign up to access all valuation multiples
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
2007
488
LTM Revenue $39.5M
LTM EBITDA -$442M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Agios Pharmaceuticals has a last 12-month revenue (LTM) of $39.5M and a last 12-month EBITDA of -$442M.
In the most recent fiscal year, Agios Pharmaceuticals achieved revenue of $36.5M and an EBITDA of -$420M.
Agios Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Agios Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $39.5M | XXX | $36.5M | XXX | XXX | XXX |
| Gross Profit | $35.2M | XXX | $32.3M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | -$442M | XXX | -$420M | XXX | XXX | XXX |
| EBITDA Margin | -1119% | XXX | -1151% | XXX | XXX | XXX |
| EBIT | -$446M | XXX | -$426M | XXX | XXX | XXX |
| EBIT Margin | -1129% | XXX | -1166% | XXX | XXX | XXX |
| Net Profit | $222M | XXX | $674M | XXX | XXX | XXX |
| Net Margin | 561% | XXX | 1846% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Agios Pharmaceuticals's stock price is $32.
Agios Pharmaceuticals has current market cap of $1.9B, and EV of $1.0B.
See Agios Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.9B | XXX | XXX | XXX | XXX | $3.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Agios Pharmaceuticals has market cap of $1.9B and EV of $1.0B.
Agios Pharmaceuticals's trades at 27.9x EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate Agios Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Agios Pharmaceuticals has a P/E ratio of 8.4x.
See valuation multiples for Agios Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 25.8x | XXX | 27.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | -2.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | 28.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.4x | XXX | 2.8x | XXX | XXX | XXX |
| EV/FCF | -7.7x | XXX | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAgios Pharmaceuticals's last 12 month revenue growth is 112%
Agios Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Agios Pharmaceuticals's rule of 40 is -1323% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Agios Pharmaceuticals's rule of X is -840% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Agios Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 112% | XXX | 96% | XXX | XXX | XXX |
| EBITDA Margin | -1119% | XXX | -1151% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1323% | XXX | -1039% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -840% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 825% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1255% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Agios Pharmaceuticals acquired XXX companies to date.
Last acquisition by Agios Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Agios Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Agios Pharmaceuticals founded? | Agios Pharmaceuticals was founded in 2007. |
| Where is Agios Pharmaceuticals headquartered? | Agios Pharmaceuticals is headquartered in United States of America. |
| How many employees does Agios Pharmaceuticals have? | As of today, Agios Pharmaceuticals has 488 employees. |
| Who is the CEO of Agios Pharmaceuticals? | Agios Pharmaceuticals's CEO is Mr. Brian Goff. |
| Is Agios Pharmaceuticals publicy listed? | Yes, Agios Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Agios Pharmaceuticals? | Agios Pharmaceuticals trades under AGIO ticker. |
| When did Agios Pharmaceuticals go public? | Agios Pharmaceuticals went public in 2013. |
| Who are competitors of Agios Pharmaceuticals? | Similar companies to Agios Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Agios Pharmaceuticals? | Agios Pharmaceuticals's current market cap is $1.9B |
| What is the current revenue of Agios Pharmaceuticals? | Agios Pharmaceuticals's last 12 months revenue is $39.5M. |
| What is the current revenue growth of Agios Pharmaceuticals? | Agios Pharmaceuticals revenue growth (NTM/LTM) is 112%. |
| What is the current EV/Revenue multiple of Agios Pharmaceuticals? | Current revenue multiple of Agios Pharmaceuticals is 25.8x. |
| Is Agios Pharmaceuticals profitable? | Yes, Agios Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Agios Pharmaceuticals? | Agios Pharmaceuticals's last 12 months EBITDA is -$442M. |
| What is Agios Pharmaceuticals's EBITDA margin? | Agios Pharmaceuticals's last 12 months EBITDA margin is -1119%. |
| What is the current EV/EBITDA multiple of Agios Pharmaceuticals? | Current EBITDA multiple of Agios Pharmaceuticals is -2.3x. |
| What is the current FCF of Agios Pharmaceuticals? | Agios Pharmaceuticals's last 12 months FCF is -$132M. |
| What is Agios Pharmaceuticals's FCF margin? | Agios Pharmaceuticals's last 12 months FCF margin is -335%. |
| What is the current EV/FCF multiple of Agios Pharmaceuticals? | Current FCF multiple of Agios Pharmaceuticals is -7.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
